‘Global Ablation Technologies Market Worth $5.7bn In 2022’ Says Visiongain Report

28 August 2018
Pharma

Visiongain’s new report Global Ablation Technologies Market Forecast 2017-2027: Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, Ophthalmology, Urology indicates that the global ablation technologies market will see $5.7bn in spending in 2022.

The global ablation technologies market is expected to grow at a CAGR of 9.4% from 2017-2022 and CAGR of 9.7% from 2022-2027. The market is expected to grow at a CAGR of 9.5% from 2017 to 2027. The market is estimated at $3.3bn in 2016, and $9.05bn in 2027.

The lead analyst of the report said: “The global ablation technologies market is mainly driven by factors such as rising incidence/prevalence of target diseases such as cancer, technological advancements, and rapid growth in the aging population having higher risk of target diseases. On the other hand, stringent regulatory requirements for product approvals, healthcare cost containment initiatives taken by various governments, are the key challenges faced by leading players in the global ablation technologies market.

The global ablation technologies market is highly competitive with RF ablation, laser ablation, ultrasound ablation, and electrical ablation as its key segments. The RF ablation segment is expected to account for the largest share of the ablation technologies market in 2017, attributing to its high safety, efficacy, and short procedural duration for the treatment of cancer, AF, and pain management, among others.”

The 212-page report contains 92 tables and 190 figures that add visual analysis in order to explain the developing trends within the Global Ablation Technologies market.

Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by technology: Radiofrequency, Ultrasound, Cyroablation, Endometrial Hydrothermal, Laser/light, Electrical and Microwave.

The report also provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by application: Cardiovascular, Oncology, Musculoskeletal, Ophthalmology, Gynaecology, Urology and Other.

The 212-page report offers market forecasts for the United States (US), Germany, France, the United Kingdom, Italy, Spain, Japan, China, India, Rest of APAC and Rest of the World.

The report Global Ablation Technologies Market Forecast 2017-2027: Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, Ophthalmology, Urology report will be of value to anyone who wants to better understand the ablation technologies market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the ablation technologies market.

Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever